The opinion of the Czech Society of Rheumatology on the treatment of rheumatic diseases and vaccination in the context of SARS-CoV-2 infection
Authors:
Šenolt Ladislav; Kolektiv Výboru České Revmatologické Společnosti: Karel Pavelka; Mann Heřman; Horák Pavel; Tegzová Dana; Olejárová Marta; Bradna Petr; Bortlík Ladislav; Šmucrová Hana; Fojtík Zdeněk; Doležalová Pavla; Forejtová Šárka; Macháček Stanislav; Dvořák Zdeněk; Sedláčková Marie; Tomčík Michal; Hrnčíř Zbyněk; Vencovský Jiří
Published in:
Čes. Revmatol., 28, 2020, No. 4, p. 197-205.
Category:
Recomendation
Overview
The pandemic of acute respiratory disease COVID-19 caused by a new type of SARS-CoV-2 coronavirus significantly affected medical practice. Patients with autoimmune inflammatory rheumatic diseases have an increased risk of infections, not only due to the high activity of the rheumatic disease but especially under the influence of long-term therapy with glucocorticoids, disease-modifying antirheumatic and immunosuppressive drugs. There has been a substantial increase in the number of often conflicting messages in the context of SARS-CoV-2 infection and rheumatic diseases. The Czech Society of Rheumatology (CRS) decided to discuss general preventive measures for SARS-CoV-2 infection, the risk of infection and the severe course of COVID-19, and the effect of disease-modifying treatment on the course of COVID-19 in rheumatic patients. An important step was also to provide rheumatologists with practical guidance on how to treat patients with an autoimmune inflammatory rheumatic disease during the COVID-19 pandemic, including a preliminary opinion on vaccination against SARS-CoV-2. The opinion of the Czech Republic is based on the provisional recommendations of the European League Against Rheumatism (EULAR), the revised version of the American College of Rheumatology (ACR), and the latest findings on COVID-19 in patients with autoimmune inflammatory rheumatic disease.
Keywords:
COVID-19 – infections – autoimmune inflammatory rheumatic diseases – disease-modifying treatment – glucocorticoids
Sources
1. Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science 2020; 367(6475): 234–235.
2. https://www.worldometers.info/coronavirus/
3. Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79(7): 851–858.
4. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2 [published online ahead of print, 2020 Jul 30]. Arthritis Rheumatol 2020; 10.1002/art.41437. doi:10.1002/art.41437
5. Lauper K, Bijlsma JWJ, Burmester GR. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Ann Rheum Dis 2021; 80(1): 26–30.
6. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52(1): 53–61.
7. Sarzi-Puttini P, Marotto D, Caporali R, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun 2020; 102545. doi:10.1016/j.jaut.2020.102545
8. Moradi S, Masoumi M, Mohammadi S, et al. Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs. Intern Emerg Med 2020; 1–5. doi:10.1007/s11739-020-02535-5
9. Aries P, Iking-Konert C. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). Ann Rheum Dis 2020; annrheumdis-2020-218400. doi:10.1136/annrheumdis-2020-218400
10. Zen M, Fuzzi E, Astorri D, Saccon F, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun 2020;112: 102502. doi: 10.1016/j.jaut.2020.102502 [Epub 2020 Jun 8]. PMID: 32527675.
11. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2020; annrheumdis-2020-218946. doi:10.1136/annrheumdis-2020-218946 [Epub ahead of print]. PMID: 33051220; PMCID: PMC7554412.
12. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest 2020; 50(10): e13362. doi:10.1111/eci.13362
13. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016; 75(6): 965–973.
14. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79(7): 859–866.
15. FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; annrheumdis-2020-218310. doi:10.1136/annrheumdis-2020-218310.
16. Serling-Boyd N, D‘Silva KM, Hsu TY, et al. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis 2020; annrheumdis-2020-219279. doi:10.1136/annrheumdis-2020-219279
17. D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, Choi HK. COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi-Center Comparative Cohort Study. Arthritis Rheumatol 2020 Dec 10. doi:10.1002/art.41619 [Epub ahead of print]. PMID: 33305544.
18. Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases [published online ahead of print, 2020 Aug 7]. Ann Rheum Dis 2020; annrheumdis-2020-217984. doi:10.1136/annrheumdis-2020-217984
19. Peach E, Rutter M, Lanyon P, et al. Risk of death among people with rare autoimmune diseases compared to the general popula-tion in England during the 2020 COVID-19 pandemic. Rheumato-logy (Oxford) 2020; keaa855. doi:10.1093/rheumatology/keaa855
20. Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun 2020; 11(1): 3774.
21. Haberman RH, Castillo R, Chen A, et al; NYU WARCOV Investigators. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol 2020; 72(12): 1981–1989.
22. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Annals of the Rheumatic Diseases 2020; 79: 667–668.
23. Salvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis 2020; 79(7): 986–988.
24. Jovani V, Calabuig I, Peral-Garrido ML, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors [published online ahead of print, 2020 Jun 25]. Ann Rheum Dis 2020; annrheumdis-2020-218152. doi:10.1136/annrheumdis-2020-218152
25. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020; annrheumdis-2020-218075. doi:10.1136/annrheumdis-2020-218075 [Epub ahead of print]. PMID: 32591357; PMCID: PMC7371570.
26. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK; and the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med 2020; e206319. doi:10.1001/jamainternmed.2020.6319 [Epub ahead of print]. PMID: 33001138; PMCID: PMC7527945.
27. Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A; COVID-19 Global Rheumatology Alliance. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol 2020; 10.1002/art.41469. doi:10.1002/art.41469 [Epub ahead of print]. PMID: 32741139; PMCID: PMC7435536.
28. Landewé RBM, Schulze-Koops H. Response to: Should patients starting biologics be screened for COVID-19? by Cardenas-de la Garza et al. [published online ahead of print, 2020 Jul 22]. Ann Rheum Dis 2020; annrheumdis-2020-218470. doi:10.1136/annrheumdis-2020-218470
29. Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020; 202(2): 149–161.
30. Chopra D, Boparai JK, Bhandari B, Srivastava A, Gupta R. Pharmacological strategies for COVID-19 – A review of the most promising repurposed antiviral drugs. Infect Disord Drug Targets 2020 Dec 18. doi:10.2174/1871526520666201218151841 [Epub ahead of print]. PMID: 33342420.
31. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med 2020; 383(19): 1813–1826.
32. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2020 Dec 11. doi:10.1056/NEJMoa2031994 [Epub ahead of print]. PMID: 33306283.
33. https://www.cdc.gov/vaccinesafety/index.html
34. Halstead SB, Katzelnick L. COVID-19 Vaccines: Should We Fear ADE? J Infect Dis 2020; 222(12): 1946–1950.
35. Chen C-M, Chen H-J, Chen W-S, et al. Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis. Int J Rheum Dis 2018; 21: 1246–1253.
36. Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015; 11(3): 135–145.
37. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79(1): 39–52.
38. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77(6): 898–904.
39. Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020; 202(2): 149–161.
40. Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45(6): 733–744.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2020 Issue 4
Most read in this issue
- L. Pitfalls of diagnosis of ANCA-associated vasculitis – case report
- Validation of Czech versions of questionnaires assessing functional impairment in patients with systemic sclerosis: Scleroderma Health Assessment Questionnaire (SHAQ), Cochin Hand Functional Scale (CHFS), Mouth Handicap in Systemic Sclerosis (MHISS), UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0)
- The opinion of the Czech Society of Rheumatology on the treatment of rheumatic diseases and vaccination in the context of SARS-CoV-2 infection
-
Low-dose computed tomography with tin filtration for the diagnosis of sacroiliitis –
our first experience